GlassScriptPhysician profile
Harris E Feinstein
NPI 1396893624
$3,670.17
in general payments reported to CMS, 2019-2025
18 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $413 · 2021: $473 · 2022: $584 · 2023: $486 · 2024: $478 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.98 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $431.08 | 2020-2025 | Caplyta |
| Alkermes, INC. | $358.59 | 2019-2024 | Lybalvi |
| Janssen Pharmaceuticals, INC | $318.37 | 2019-2022 | |
| Neos Therapeutics, LP | $264.68 | 2022-2023 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $257.29 | 2019-2024 | Abilify Maintena |
| Axsome Therapeutics, INC. | $242.98 | 2023-2024 | Sunosi, Auvelity |
| Tris Pharma INC | $229.29 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Sunovion Pharmaceuticals INC. | $202.54 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $184.09 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $141.85 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $105.98 | 2019-2020 | |
| Indivior INC. | $81.47 | 2019-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50.16 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.92 | 2019 | |
| Allergan, INC. | $41.91 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harris Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.